RLYB•benzinga•
Rallybio Highlights 2024 Achievements; Announces 2025 Milestones, RLYB212 Phase 2 Participant Dosing In Q2 2025, RLYB116 PK/PD Study Launch In Q2 2025, REV102 IND-Enabling Studies Planned For 2025; FNAIT Study Screening To Conclude January 2025.
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 10, 2025 by benzinga